{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:32:40Z","timestamp":1767648760320,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.pupt.2019.101830","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T19:38:52Z","timestamp":1563824332000},"page":"101830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose"],"prefix":"10.1016","volume":"58","author":[{"given":"Corrado","family":"Pelaia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Busceti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Francesco","family":"Rago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2019.101830_bib1","doi-asserted-by":"crossref","first-page":"15025","DOI":"10.1038\/nrdp.2015.25","volume":"1","author":"Holgate","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.pupt.2019.101830_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","article-title":"The global burden of asthma: executive summary of the GINA dissemination committee report","volume":"59","author":"Masoli","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2019.101830_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMra0804579","article-title":"Drug therapy: asthma","volume":"360","author":"Fanta","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2019.101830_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nrd3792","article-title":"The potential of biologics for the treatment of asthma","volume":"11","author":"Pelaia","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pupt.2019.101830_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2019.101830_bib6","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"author":"Global Initiative for Asthma","key":"10.1016\/j.pupt.2019.101830_bib7"},{"key":"10.1016\/j.pupt.2019.101830_bib8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.201809-1817PP","article-title":"Unmet needs in severe asthma subtyping and precision medicine trials. Bridging clinical and patient perspectives","volume":"199","author":"Siddiqui","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101830_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101830_bib10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2019.101830_bib11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthma. The Belgian severe asthma registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2019.101830_bib12","doi-asserted-by":"crossref","first-page":"879783","DOI":"10.1155\/2015\/879783","article-title":"Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma","author":"Pelaia","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.pupt.2019.101830_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and non-eosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101830_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.pupt.2019.101830_bib15","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/ajrccm.164.8.2010002","article-title":"Interleukin-5 induces CD34+ eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma","volume":"164","author":"Stirling","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101830_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd3838","article-title":"Targeting eosinophils in allergy, inflammation and beyond","volume":"12","author":"Fulkerson","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pupt.2019.101830_bib17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major sub-phenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2019.101830_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(00)00690-7","article-title":"Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone","volume":"406","author":"Zhang","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pupt.2019.101830_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01167-2017","article-title":"Asthma and corticosteroids: time for a more precise approach to treatment","volume":"49","author":"Dunican","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2019.101830_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/104315","article-title":"Update on anticytokine treatment for asthma","author":"Gallelli","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pupt.2019.101830_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40259-017-0215-8","article-title":"Interleukin-5 inhibitors for severe asthma: rationale and future outlook","volume":"31","author":"Shrimanker","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.pupt.2019.101830_bib22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14712598.2018.1492540","article-title":"Biological therapies for eosinophilic asthma","volume":"18","author":"Patel","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.pupt.2019.101830_bib23","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","article-title":"Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.pupt.2019.101830_bib24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/TCRM.S111862","article-title":"Role of biologics in severe eosinophilic asthma: focus on reslizumab","volume":"12","author":"Pelaia","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.pupt.2019.101830_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17425255.2018.1421170","article-title":"Pharmacokinetic\/pharmacodynamic profile of reslizumab in asthma","volume":"14","author":"Matera","year":"2018","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.pupt.2019.101830_bib26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425255.2017.1359253","article-title":"Pharmacokinetic\/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma","volume":"13","author":"Matera","year":"2017","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.pupt.2019.101830_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1358\/dot.2017.53.12.2736670","article-title":"Benralizumab for the treatment of asthma","volume":"53","author":"Matera","year":"2017","journal-title":"Drugs Today"},{"key":"10.1016\/j.pupt.2019.101830_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/DDDT.S155307","article-title":"Benralizumab in the treatment of severe asthma: design, development and potential place in therapy","volume":"21","author":"Pelaia","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.pupt.2019.101830_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","author":"Pelaia","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pupt.2019.101830_bib30","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2019.101830_bib31","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2019.101830_bib32","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2019.101830_bib33","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2019.101830_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2019.101830_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.pupt.2019.101830_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"Benralizumab: a new approach for the treatment of severe eosinophilic asthma","volume":"29","author":"Gonzalez","year":"2019","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.pupt.2019.101830_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1371","article-title":"Relationship between benralizumab exposure and efficacy for patients with severe eosinophilic asthma","author":"Chya","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2019.101830_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fmed.2017.00101","article-title":"Homeostatic eosinophils: characteristics and functions","volume":"4","author":"Marichal","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.pupt.2019.101830_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The asthma control test and the asthma control questionnaire for assessing asthma control: systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2019.101830_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2019.101830_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pupt.2018.11.002","article-title":"Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: results of a 5-year single-centre observational study","volume":"54","author":"Pelaia","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2019.101830_bib42","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2019.101830_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/imt-2017-0161","article-title":"Benralizumab: an anti-IL-5 receptor \u03b1 monoclonal antibody in the treatment of asthma","volume":"10","author":"Kupczyk","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.pupt.2019.101830_bib44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.anai.2019.02.016","article-title":"Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma","volume":"122","author":"Chupp","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.pupt.2019.101830_bib45","doi-asserted-by":"crossref","first-page":"212580","DOI":"10.7573\/dic.212580","article-title":"Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?","volume":"8","author":"Menzella","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.pupt.2019.101830_bib46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MOH.0b013e328331fae9","article-title":"Role of interleukins in the regulation of basophil development and secretion","volume":"17","author":"Valent","year":"2010","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.pupt.2019.101830_bib47","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor \u03b1 mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2019.101830_bib48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","article-title":"Immunological decision-making: how does the immune system decide to mount a helper T-cell response?","volume":"123","author":"Kaiko","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.pupt.2019.101830_bib49","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jaci.2016.06.032","article-title":"Human circulating group 2 innate lymphoid cells can express CD154 and promote IgE production","volume":"139","author":"Maggi","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2019.101830_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.alit.2018.11.001","article-title":"Airway innate lymphoid cells in the induction and regulation of allergy","volume":"68","author":"Doherty","year":"2019","journal-title":"Allergol. Int."},{"key":"10.1016\/j.pupt.2019.101830_bib51","doi-asserted-by":"crossref","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2019.101830_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/medicina55040095","article-title":"Inflammation and endotyping in chronic rhinosinusitis \u2013 a paradigm shift","volume":"55","author":"Ahern","year":"2019","journal-title":"Medicina"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919301282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919301282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:28:51Z","timestamp":1761082131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553919301282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":52,"alternative-id":["S1094553919301282"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101830","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101830"}}